Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer

Kathy Miller, Judy Sisk, Rafat Ansari, Gary Gize, Sreenivasa Nattam, Kenneth Pennington, Frank Monaco, George W. Sledge

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing metastatic breast cancer. To date, 27 patients have received paclitaxel at 175 mg/m2 over 3 hours on day 1, plus gemcitabine at 1,200 mg/m2 on days 1 and 8, plus trastuzumab at a 4-mg/kg loading dose on day 1, followed by 2 mg/kg weekly. Treatment cycles were repeated every 21 days. Responding or stable patients who had received six cycles of combination therapy continued single-agent trastuzumab weekly until disease progression. Treatment was generally well tolerated with grade 4 toxicity limited to myelo-suppression. In all, 12 patients have achieved a partial remission and I patient had progressive disease; 14 patients continue treatment and have not yet been evaluated for response. Combination treatment with paclitaxel, gemcitabine, and trastuzumab is well tolerated and appears to be highly active. Accrual will continue to a total enrollment of 46 patients.

Original languageEnglish
Pages (from-to)38-40
Number of pages3
JournalOncology (Williston Park, N.Y.)
Volume15
Issue number2 SUPPL. 3
StatePublished - 2001

Fingerprint

gemcitabine
Paclitaxel
Breast Neoplasms
Therapeutics
Trastuzumab
Disease Progression

ASJC Scopus subject areas

  • Oncology

Cite this

Miller, K., Sisk, J., Ansari, R., Gize, G., Nattam, S., Pennington, K., ... Sledge, G. W. (2001). Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Williston Park, N.Y.), 15(2 SUPPL. 3), 38-40.

Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. / Miller, Kathy; Sisk, Judy; Ansari, Rafat; Gize, Gary; Nattam, Sreenivasa; Pennington, Kenneth; Monaco, Frank; Sledge, George W.

In: Oncology (Williston Park, N.Y.), Vol. 15, No. 2 SUPPL. 3, 2001, p. 38-40.

Research output: Contribution to journalArticle

Miller, K, Sisk, J, Ansari, R, Gize, G, Nattam, S, Pennington, K, Monaco, F & Sledge, GW 2001, 'Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer', Oncology (Williston Park, N.Y.), vol. 15, no. 2 SUPPL. 3, pp. 38-40.
Miller K, Sisk J, Ansari R, Gize G, Nattam S, Pennington K et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Williston Park, N.Y.). 2001;15(2 SUPPL. 3):38-40.
Miller, Kathy ; Sisk, Judy ; Ansari, Rafat ; Gize, Gary ; Nattam, Sreenivasa ; Pennington, Kenneth ; Monaco, Frank ; Sledge, George W. / Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. In: Oncology (Williston Park, N.Y.). 2001 ; Vol. 15, No. 2 SUPPL. 3. pp. 38-40.
@article{3915b61593e0415b9d29f7cbceff4ca1,
title = "Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer",
abstract = "A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing metastatic breast cancer. To date, 27 patients have received paclitaxel at 175 mg/m2 over 3 hours on day 1, plus gemcitabine at 1,200 mg/m2 on days 1 and 8, plus trastuzumab at a 4-mg/kg loading dose on day 1, followed by 2 mg/kg weekly. Treatment cycles were repeated every 21 days. Responding or stable patients who had received six cycles of combination therapy continued single-agent trastuzumab weekly until disease progression. Treatment was generally well tolerated with grade 4 toxicity limited to myelo-suppression. In all, 12 patients have achieved a partial remission and I patient had progressive disease; 14 patients continue treatment and have not yet been evaluated for response. Combination treatment with paclitaxel, gemcitabine, and trastuzumab is well tolerated and appears to be highly active. Accrual will continue to a total enrollment of 46 patients.",
author = "Kathy Miller and Judy Sisk and Rafat Ansari and Gary Gize and Sreenivasa Nattam and Kenneth Pennington and Frank Monaco and Sledge, {George W.}",
year = "2001",
language = "English",
volume = "15",
pages = "38--40",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "2 SUPPL. 3",

}

TY - JOUR

T1 - Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer

AU - Miller, Kathy

AU - Sisk, Judy

AU - Ansari, Rafat

AU - Gize, Gary

AU - Nattam, Sreenivasa

AU - Pennington, Kenneth

AU - Monaco, Frank

AU - Sledge, George W.

PY - 2001

Y1 - 2001

N2 - A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing metastatic breast cancer. To date, 27 patients have received paclitaxel at 175 mg/m2 over 3 hours on day 1, plus gemcitabine at 1,200 mg/m2 on days 1 and 8, plus trastuzumab at a 4-mg/kg loading dose on day 1, followed by 2 mg/kg weekly. Treatment cycles were repeated every 21 days. Responding or stable patients who had received six cycles of combination therapy continued single-agent trastuzumab weekly until disease progression. Treatment was generally well tolerated with grade 4 toxicity limited to myelo-suppression. In all, 12 patients have achieved a partial remission and I patient had progressive disease; 14 patients continue treatment and have not yet been evaluated for response. Combination treatment with paclitaxel, gemcitabine, and trastuzumab is well tolerated and appears to be highly active. Accrual will continue to a total enrollment of 46 patients.

AB - A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing metastatic breast cancer. To date, 27 patients have received paclitaxel at 175 mg/m2 over 3 hours on day 1, plus gemcitabine at 1,200 mg/m2 on days 1 and 8, plus trastuzumab at a 4-mg/kg loading dose on day 1, followed by 2 mg/kg weekly. Treatment cycles were repeated every 21 days. Responding or stable patients who had received six cycles of combination therapy continued single-agent trastuzumab weekly until disease progression. Treatment was generally well tolerated with grade 4 toxicity limited to myelo-suppression. In all, 12 patients have achieved a partial remission and I patient had progressive disease; 14 patients continue treatment and have not yet been evaluated for response. Combination treatment with paclitaxel, gemcitabine, and trastuzumab is well tolerated and appears to be highly active. Accrual will continue to a total enrollment of 46 patients.

UR - http://www.scopus.com/inward/record.url?scp=0035257198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035257198&partnerID=8YFLogxK

M3 - Article

C2 - 11252888

AN - SCOPUS:0035257198

VL - 15

SP - 38

EP - 40

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 2 SUPPL. 3

ER -